Oligonucleotide Synthesis Market Overview
The global oligonucleotide synthesis market generated $1.5 billion revenue in 2017 and is projected to advance at a CAGR of 10.8% during 2018–2023. The market is mainly driven by increasing research activities in synthetic biology, rising prevalence of cancer and infectious diseases, advancements in oligonucleotide synthesis technologies, and favorable government regulations.
GLOBAL OLIGONUCLEOTIDE SYNTHESIS, BY OFFERING, $M (2013-2023)
Based on offering, the oligonucleotide synthesis market is categorized into synthesized oligonucleotides, reagents and consumables, and equipment. During the forecast period, the market is expected to witness the fastest growth in the category of synthesized oligonucleotides, with a CAGR of 11.1%. The demand for synthesized oligonucleotides is expected to increase in the coming years, on account of the growing trend of contract manufacturing of oligonucleotides.
On the basis of application, the oligonucleotide synthesis market is categorized into research, diagnostics, and therapeutics. Of these, the fastest growth in the market during the forecast period is expected from research applications, with a CAGR of 11.1%. The surge in the demand for oligonucleotides for diagnostic purposes can be attributed to their growing application in the molecular diagnosis of inherited disorders.
Based on end user, the oligonucleotide synthesis market is classified into academic research institutes, diagnostic laboratories, pharmaceutical and biotechnology companies, and others, where “others” include food and beverage companies and forensic laboratories. Among all end users, academic research institutes held the largest share in the market during the historical period.
During the forecast period, the market is expected to observe the fastest growth in Asia-Pacific (APAC), at a CAGR of 11.6%. The growth of the APAC oligonucleotide synthesis market can be majorly attributed to the improving healthcare infrastructure, increasing need for better health outcomes, and rising prevalence of chronic and infectious diseases in the region.
According to the World Health Organization (WHO), in 2012, about 3.1 million and about 1.0 million cancer cases (excluding non-melanoma skin cancer) were reported from China and India, respectively. The Foundation for AIDS Research (amfAR) estimated that around 300,000 people in APAC became newly infected with HIV in 2015, bringing the total number of people living with HIV in the region to 5.1 million. amfAR also reported that AIDS-related illnesses claimed 180,000 lives in the region during the same year. Thus, the rising prevalence of chronic and infectious diseases in APAC is expected to provide ample growth opportunities to the oligonucleotide synthesis market players in the region.
Oligonucleotide Synthesis Market Dynamics
Advancements in oligonucleotide synthesis and increasing research activities in synthetic biology are driving the growth of the oligonucleotide synthesis market. Recent advances in synthesis techniques have led to the cost-effective and faster synthesis of oligomers. Besides, the development of high-throughput synthesizers, new sets of protecting amino groups, and better coupling reagents has revolutionized the synthesis of oligonucleotides.
The development of microarray technology has also supported the oligonucleotide product development for therapeutic and diagnostic applications. For instance, a large number of oligonucleotide conjugates with biological ligands have been researched, which are increasingly being used in the diagnosis of a number of inherited disorders. Besides, advancements in microchip-based oligonucleotide synthesis have led to an increase in the throughput and reduction in the cost of the synthesis of oligonucleotides. Moreover, advancements in enzymatic error correction technologies have reduced the occurrence of errors in synthesized products. Hence, these advancements continue to bolster the growth of the global oligonucleotide synthesis market.
Growing focus on personalized medicine is expected to positively impact the growth of the oligonucleotide synthesis market during the forecast period. Personalized medicine offers tailored medical treatment based on individual needs and preferences of patients. Oligonucleotide synthesis helps in offering personalized solutions to ill patients. The advent of anti-sense RNA therapeutic has gained enormous traction in the biotechnology industry. The potential application of personalized medicine to treat rare diseases is achievable with oligonucleotide synthesis. With advancements in oligonucleotide synthesis, patients can be treated and diagnosed more effectively. Therefore, growing focus on personalized medicine is expected to create ample opportunities for the players operating in the market.
Oligonucleotide Synthesis Market Competitive Landscape
The companies operating in the oligonucleotide synthesis industry are expanding and developing their product portfolio. For instance, in October 2017, Thermo Fisher Scientific Inc. commercially launched the Applied Biosystems Axiom Africa Array for medical and population genomics to accelerate and support initiatives in global health and population research. The Wellcome Trust Sanger Institute and Thermo Fisher Scientific combined their respective expertise in human genomic analysis and informatics to co-develop the Axiom Africa Array. The array helps capture the genome-wide variation in African, Asian, and European populations.
Similarly, in May 2017, Thermo Fisher Scientific Inc., expanded its line of endotoxin-free plasmid DNA isolation products with the launch of the PureLink Expi endotoxin-free maxi plasmid purification kit. The kit allows researchers to yield up to 1.5 mg of endotoxin-free, advanced-transfection-quality plasmid DNA in less than 90 minutes. The kit uses novel, proprietary anion-exchange membrane-based columns, in combination with a vacuum-assisted workflow, to isolate advanced transfection-grade plasmid DNA in about half the time of current standard protocols.
Some of the other key players operating in the oligonucleotide synthesis industry are General Electric Company, Merck KGaA, Eurofins Scientific SE, LGC Biosearch Technologies Inc., Integrated DNA Technologies Inc., GeneDesign Inc., Nitto Denko Avecia Inc., Trilink Biotechnologies LLC, and Kaneka Eurogentec S.A.